newsfilter
← Latest News
GlobeNewswire·

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) --